French Medtech System ‘Too Rigorous’ For Innovation To Flourish, Argues Healthtech Expert
Executive Summary
David Caumartin is well versed in the both the benefits and drawbacks of being a France-based medtech innovator, having spent almost three decades in the local industry. The VP of France Biotech spoke to Medtech Insight about the new opportunities there to be seized, and the pitfalls to avoid.
You may also be interested in...
Bernasconi: Europe Needs A Better Strategic Rudder For Medtech Innovation Policy
Always ready to frame the needs of EU medtechs clearly and succinctly, MedTech Europe CEO Serge Bernasconi says that the local industry in the future could benefit from more strategic direction and support from a dedicated EU agency or similar tighter governance structure.
Start-Up Spotlight: CorWave Takes Inspiration From Nature To Tackle Heart Failure
Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.